BioAtla, Inc. is a pharmaceutical company based in the United States, specializing in the development of innovative antibody-based therapies for solid tumor cancer treatment. With a Risk Rating Score of 27.0, BioAtla is considered a medium-risk investment. The company's ESG score reflects its commitment to environmental sustainability and governance practices. BioAtla's pipeline includes unique products like mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021), as well as several promising antibody programs in Phase 1 clinical trials.